Marksans Pharma Limited (MARKSANS) AI Stock Analysis

• Market Cap: ₹79.15B
• Dividend Yield: 0.44%
• Average Volume (3M): 99.03K
• Price to Earnings (P/E): 18.0
• Beta (1Y): 1.54
• Revenue Growth: 14.80%
• EPS Growth: 1.35%
• Country: IN
• Employees: 1,141
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 2.50
• Shares Outstanding: 453,163,760
• 10 Day Avg. Volume: 119,310
• 30 Day Avg. Volume: 99,030
• PEG Ratio: 1.24
• Price to Book (P/B): 4.08
• Price to Sales (P/S): 3.83
• P/FCF Ratio: 298.02
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 10.27
• Revenue Forecast (FY): ₹32.32B

• Rating: 71 Outperform
• Price Target: ₹174.00 ▼(-4.42% Downside)
• Action: Upgraded Date: 02/04/26
• Date: Action: Upgraded 02/04/26

The score is driven mainly by strong financial performance—solid growth, improving margins, and low leverage—tempered by softer operating cash flow conversion. Technical indicators are mixed with negative MACD and longer-term weakness versus the 200-day average, while valuation appears reasonable but with a low dividend yield.

Positive Factors

Strong revenue growth and margins

Marksans' ~20.45% revenue growth coupled with a 56.38% gross margin and 14.51% net margin indicate durable demand and effective cost control across its product mix. Sustained high margins support reinvestment in manufacturing, regulatory filings and commercial expansion, bolstering earnings resilience over the medium term.

Negative Factors

Weak operating cash flow conversion

Operating cash flow declined 10.28% and OCF converts only ~54% of reported net income, indicating weaker cash realization from operations. If persistent, this constrains self-funding of working capital and regulatory filings, potentially forcing more external financing or slower product rollouts over time.

Marksans Pharma Limited Business Overview & Revenue Model

Company Description

Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, ben...

Read more

Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, ben...

How the Company Makes Money

Marksans primarily makes money by selling pharmaceutical and healthcare products, with revenue largely derived from (1) finished-dosage generic formulations sold into domestic and export markets and (2) OTC products sold through consumer healthcar...

Read more

Marksans primarily makes money by selling pharmaceutical and healthcare products, with revenue largely derived from (1) finished-dosage generic formulations sold into domestic and export markets and (2) OTC products sold through consumer healthcar...

Marksans Pharma Limited Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	27.31B	26.23B	21.77B	18.52B	14.80B	13.68B
Gross Profit	15.37B	14.79B	11.03B	9.31B	7.32B	7.50B
EBITDA	5.62B	5.29B	5.09B	3.99B	3.01B	3.46B
Net Income	3.52B	3.81B	3.14B	2.66B	1.85B	2.39B
Balance Sheet
Total Assets	34.42B	32.40B	26.81B	21.90B	16.40B	12.28B
Cash, Cash Equivalents and Short-Term Investments	6.71B	7.05B	7.00B	7.19B	3.47B	2.12B
Total Debt	3.32B	3.22B	2.44B	1.23B	1.11B	341.02M
Total Liabilities	7.28B	7.50B	5.95B	4.25B	4.17B	3.23B
Stockholders Equity	26.88B	24.67B	20.65B	17.45B	12.02B	8.86B
Cash Flow
Free Cash Flow	19.97M	337.45M	215.69M	1.84B	529.27M	1.32B
Operating Cash Flow	751.86M	2.07B	2.30B	2.37B	992.57M	1.79B
Investing Cash Flow	-364.77M	-490.09M	-1.41B	-2.59B	-416.86M	-448.96M
Financing Cash Flow	-528.77M	-651.46M	-687.27M	1.98B	795.11M	-152.86M

Marksans Pharma Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 182.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MARKSANS, the sentiment is Neutral. The current price of 182.05 is above the 20-day moving average (MA) of 166.88, above the 50-day MA of 171.75, and below the 200-day MA of 190.86, indicating a neutral trend. The MACD of -1.95 indicates Negative momentum. The RSI at 51.49 is Neutral, neither overbought nor oversold. The STOCH value of 77.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:MARKSANS.

Marksans Pharma Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUROPHARMA	79 Outperform	₹775.43B	18.87	―	0.33%	7.33%	-3.79%
IPCALAB	73 Outperform	₹366.69B	27.58	―	0.28%	9.66%	25.79%
MARKSANS	71 Outperform	₹79.15B	18.03	―	0.44%	14.80%	1.35%
DRREDDY	70 Outperform	₹993.96B	21.88	―	0.63%	14.10%	9.72%
LAURUSLABS	66 Neutral	₹584.58B	59.42	―	0.15%	25.83%	421.20%
GLENMARK	53 Neutral	₹613.60B	35.61	―	0.24%	30.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Marksans Pharma Limited Corporate Events